Company Filing History:
Years Active: 2013
Title: **Innovator Spotlight: Kimberley A. Lentz**
Introduction
Kimberley A. Lentz, a prominent inventor based in Durham, Connecticut, has made significant contributions to the field of medical science through her innovative work on compounds targeting the nicotinic α7 receptor. With one patent to her name, she focuses on advancing therapies for central nervous system disorders.
Latest Patents
Lentz's notable patent is titled "Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs." This patent outlines a variety of compounds, including their salts, and presents compositions and methods for their application. These prodrugs function as ligands, agonists, and partial agonists, demonstrating potential in treating various affective and neurodegenerative disorders.
Career Highlights
Currently, Kimberley A. Lentz is associated with Bristol-Myers Squibb Company, a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines. Her work contributes significantly to the development of new therapies that can change patients' lives.
Collaborations
In her professional journey, Lentz collaborates with skilled colleagues such as Rex Denton and James H Cook, II. These partnerships foster a creative environment that drives advancements in research and development, particularly in the realm of neuroscience.
Conclusion
Kimberley A. Lentz exemplifies dedication and innovation in her field. Through her patent and collaboration with leading professionals, she continues to impact the development of treatments for complex disorders of the central nervous system. Her work not only showcases the potential of chemical compounds but also highlights the importance of collaboration in achieving groundbreaking advancements in medicine.